Loading stock data…
$5.17+0.04 (+0.78%)
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States.
Tonix Pharmaceuticals Holding Corp. in the Healthcare sector is trading at $5.17 with a market capitalization of $211M. Wall Street consensus targets $44.25 (4 analysts), implying a +755.9% move over the next 12 months. The stock is currently near its 52-week low of $5.01, remaining 59.4% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 11 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $13.54M↑ | $6.88M↑ | $5.39M↑ | $3.29M↑ | $2.00M |
| Gross Profit | $12.84M↑ | $5.30M↑ | $4.33M↑ | $1.92M↑ | -$1.27M |
| Operating Income | -$41.94M↓ | -$41.54M↑ | -$48.22M↓ | -$32.09M↓ | -$27.26M |
| Net Income | -$40.55M↓ | -$40.19M↑ | -$46.91M↓ | -$32.01M↓ | -$28.27M |
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United ...